
Pharmaceutical Executive-01-01-2005


Pharmaceutical Executive
Citing cherry-picked patients, unrealistic dosing, and placebo control, payers will increasingly require that the proof for payment of drugs must come from head-to-head trials.

Pharmaceutical Executive
Heading the WHO list are pandemic influenza and antibiotic-resistant bacterial infections. Together the two could kill millions.
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site
2
Pharmaceutical Executive Daily: FDA Shelves CNPV Program
3
FDA Pauses Commissioner’s National Priority Voucher Program: Report
4
When Small Protocol Decisions Become Enrollment or Retention Barriers
5